Source: Seeking Alpha

Sunesis: Sunesis rises 1.9% after Viracta sees registration trial in H1 for lymphoma regimen

Read full article »
Sunesis's Competitors | Sunesis's News | Sunesis's Financials
Stay up-to-date with the latest news on Sunesis
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Dayton Misfeldt's photo - Interim-CEO of Sunesis

Interim-CEO

Dayton Misfeldt

CEO Approval Rating

86/100

Read more
Stay up-to-date with the latest news on Sunesis